Shares in Vertex jump on overnight success of CF triple ther...

Shares in US pharma Vertex were up sharply in premarket trading after its newly-launched cystic fibrosis triple therapy attained blockbuster status almost overnight, leading

The 4 biggest pharma market access stories of 2019

What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive into the pharmaphorum archives to find out.

After four-year wait, patients in England finally get Vertex...

NHS England has signed an agreement with US pharma Vertex covering all the company’s licensed cystic fibrosis medicines, and any future uses for them.

Vertex looks beyond cystic fibrosis with $950m Semma buy

Scotland's cost regulator rejects Vertex cystic fibrosis dru...

Scotland’s cost-effectiveness body has rejected regular NHS funding for Vertex’s cystic fibrosis drugs Orkambi and Symkevi because of concerns about whether their high costs justify uncerta

Minister says using generic CF drug is an option in Orkambi ...

Vertex is coming under increased pressure to sign a deal with the NHS covering its Orkambi cystic fibrosis (CF) drug, with a government minister suggesting she would consider implementing l